Phage therapy program
MB Pharma / DUOFAG
| Status | Research/development |
|---|---|
| Type | Company |
| Location | Prague; Czech Republic |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Company development/manufacturing contact; trial participation should be assessed through current study sites, not assumed from a corporate product page. |
|---|---|
| Areas of work | DUOFAG topical phages for S. aureus and P. aeruginosa wounds/ulcers; official timeline reports Phase I completed July 2025, Phase IIA recruitment and Phase IIB approval February 2026. |
| International access | No present blanket international trial or compassionate eligibility established. |
What to confirm
- Company trial-stage claims need confirmation with a current national/EU registry and site contacts.
- Do not confuse DUOFAG live phages with separate bacterial lysate products.
Related studies(1)
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
Status unconfirmed
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | eu-mb-pharma-duofag |
|---|